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General Methods. (5S,6S,7S,8R,8aR)-5,6,7,8-Tetrahydroxy-2-oxa-3-
oxoindolizidine (4) and its corresponding per-O-acetyl derivative (8) were prepared 
according to literature procedures.1 Reagents and solvents were purchased from 
commercial sources and used without further purification. Optical rotations were 
measured at 22 ºC in 1-dm tubes on a Perkin-Elmer 141 MC polarimeter. 1H (and 13C) 
NMR spectra were recorded at 500 (125.7) MHz with Bruker 500 DRX instrument. 2D 
COSY and HMQC experiments were carried out to assist in signal assignment. TLC 
was performed with precoated TLC plates, silica gel 30F-245, with visualization by UV 
light and by charring with 10% H2SO4 or 0.2% w/v cerium (IV) sulphate-5% 
ammonium molybdate in 2 M H2SO4 or 0.1% ninhydrine in EtOH. Column 
chromatography was carried out with Silica Gel 60 (230-400 mesh). Semi-preparative 
HPLC was carried out on an Agilent Series 1100 instrument. A Spherisorb column (5 
µm Silica, 10 x 250 mm), flow rate of 2.0 mL/min and 1100 Series refractive index 
detector -model number G1362A (Agilent Technologies)- were used. For ESI mass 
spectra, 0.1 pM sample concentrations were used, the mobile phase consisting of 50% 
aq acetonitrile at 0.1 mL min-1 and were obtained with a Bruker Esquirre 6000 
instrument. Elemental analyses were performed at the Instituto de Investigaciones 
Químicas (Sevilla, Spain). 
                                                 
1 V. M. Díaz Pérez, M. I. García Moreno, C. Ortiz Mellet, J. Fuentes, J. C. Díaz Arribas, J. Cañada, J. M. 
García Fernández, J. Org. Chem., 2000, 65, 136-143. 
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  General Procedures for Inhibition Assay. The glycosidases α-glucosidase (from 
yeast), β-glucosidase (from almonds), β-glucosidase (from bovine liver, cytosolic), α-
galactosidase (from green coffee beans), trehalase (from pig kidney), amyloglucosidase 
(from Aspergillus niger), α-mannosidase (from jack bean), β-mannosidase (from Helix 
pomatia) and β-galactosidase (from E. coli) used in the inhibition studies, as well as the 
corresponding o- and p-nitrophenyl glycoside substrates, were purchased from Sigma 
Chemical Co. Inhibitory potencies were determined by spectrophotometrically 
measuring the residual hydrolytic activities of the glycosidases against the respective o- 
(for β-glucosidase/β-galactosidase from bovine liver and β-galactosidase from E. coli) 
or p-nitrophenyl α- or β-D-glycopyranoside or α,α´-trehalose (for trehalase), in the 
presence of the corresponding gem-diamine derivative. Each assay was performed in 
phosphate or phosphate-citrate (for α- or β-mannosidase or amyloglucosidase) buffer at 
the optimal pH for each enzyme. The Km values for the different glycosidases used in 
the tests and the corresponding working pHs are listed herein: α-glucosidase (yeast), Km 
= 0.35 mM (pH 6.8); β-glucosidase (almonds), Km = 3.5 mM (pH 7.3); β-glucosidase 
(bovine liver), Km = 2.0 mM (pH 7.3); β-galactosidase (E. coli), Km = 0.12 mM (pH 
7.3); α-galactosidase (coffee beans), Km = 2.0 mM (pH 6.8); trehalase (pig kidney), Km 
= 4.0 mM (pH 6.2); amyloglucosidase (Aspergillus niger), Km = 3.0 mM (pH 5.5); β-
mannosidase (Helix pomatia), Km = 0.6 mM (pH 5.5); α-mannosidase (jack bean), Km = 
2.0 mM (pH 5.5). The reactions were initiated by addition of enzyme to a solution of the 
substrate in the absence or presence of various concentrations of inhibitor. After the 
mixture was incubated for 10-30 min at 37 ºC or 55 ºC the reaction was quenched by 
addition of 1 M Na2CO3 or a solution of Glc-Trinder (Sigma, for trehalase). The 
absorbance of the resulting mixture was determined at 405 nm or 505 nm. The Ki value 
and enzyme inhibition mode were determined from the slope of Lineweaver-Burk plots 
and double reciprocal analysis using a Microsoft Office Excel 2003 program. 
Cell culture. MCF-7 cells were grown in Eagle’s minimum essential medium 
(EMEM; Invitrogen) containing 5% foetal calf serum (Cambrex), 2 mM L-glutamine 
(Invitrogen), 0.06% HEPES (Invitrogen) and penicillin (50 IU/ml)/ streptomycin (50 
µg/ml; Invitrogen) at 37 °C in a humidified atmosphere of 5% CO2 in air. The growth 
media was renewed every 2 days. 
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Cell count and viability. Compounds 5α, 6α and 7α were diluted out in 
DMSO. Final concentrations were obtained by appropriate dilution in an external 
control solution. The final DMSO concentration was < 0.1%. MCF-7 cells were grown 
in 60-mm Petri dishes at a density of 1x105 cells/dish and allowed to attach overnight 
and subsequently incubated for 72 h in the same medium supplemented with different 
concentrations of 6, 7 and 8. MCF-7 growth was assessed using the standard Malassez 
cell method. Briefly, cells were removed by trypsinisation and diluted in Trypan blue. 
Cell counts were performed 6 times (in a blind manner) and the results were expressed 
as the percentage of viable cells measured compared to those measured under control 
conditions. 
Statistical analysis. Data are presented as means ± SD (n = number of 
individual experiments). Plots were produced using Origin 7.0 (Microcal Software, Inc). 
The ANOVA one way with Holm-sidak post hoc test was performed using Sigma Stat 
software to compare treatment means with control means and to test significant 
differences. Differences between values were considered significant (*) when P < 0.05; 
very significant (**) when P < 0.01 and highly significant (***) when P < 0.001. 
Preparation of (5S and 5R,6S,7S,8R,8aR)-5-octylamino-6,7,8-trihydroxy-2-
oxa-3-oxoindolizidine (5): A solution of the 5-hydroxy-2-oxa-3-oxoindolizidine 
derivative 4 (152 mg, 0.74 mmol) and n-octylamine (124 μL, 0.74 mmol) in MeOH (1 
mL) was stirred at 65 ºC for 2 h (TLC monitoring). The solvent was eliminated under 
reduced pressure to afford the corresponding glycosylamine 6 (68% yield) as a mixture 
of the corresponding α and β anomers; α:β ratio 6:1 (H-5 integration). The α-anomer 
(6α) was separated in pure form by subsequent column chromatography (20:1 → 10:1 
CH2Cl2-MeOH). 
(5S,6S,7S,8R,8aR)-5-Octylamino-6,7,8-trihydroxy-2-oxa-3-oxoindolizidine 
(5α): Yield: 142 mg (60%). Rf 0.45 (9:1 CH2Cl2-MeOH). [α]D +69.2 (c 1.0 in MeOH). 
1H NMR (500 MHz, MeOD) δ 4.64 (d, 1 H, J5,6 = 5.0 Hz, H-5), 4.50 (t, 1 H, J1a,8a = 
J1a,1b = 8.5 Hz, H-1a), 4.29 (dd, 1 H, J1b,8a = 5.0 Hz, H-1b), 3.85 (ddd, 1 H, J8a,8 = 9.5 
Hz, H-8a), 3.63 (t, 1 H, J6,7 = J7,8 = 9.5 Hz, H-7), 3.49 (dd, 1 H, H-6), 3.28 (t, 1 H, H-8), 
2.60 (m, 2 H, CH2NH), 1.53 (m, 2 H, CH2CH2NH), 1.35 (m, 10 H, CH2), 0.92 (t, 3 H, 
3JH,H = 7.0 Hz, CH3). 13C NMR (125.7 MHz, MeOD) δ 160.5 (CO), 76.9 (C-8), 75.8 (C-
7), 73.6 (C-6), 70.8 (C-5), 69.2 (C-1), 55.9 (C-8a), 48.8 (CH2NH), 34.3-25.0 (CH2), 
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15.7 (CH3). ESIMS: m/z 339.2 [M + Na]+. Anal. Calcd for C15H28N2O5: C, 56.94; H, 
8.92; N, 8.85. Found: C, 56.76; H, 8.83; N, 8.71. 
(5R,6R,7S,8R,8aR)-5-Fluoro-6,7,8-tri-O-acetyl-2-oxa-3-oxoindolizidine (10): 
Compound 9 (560 mg, 1.50 mmol) was placed in a polyethylene vessel cooled at -40 ºC 
and treated with poly(hydrogen fluoride)pyridinimum complex (70% HF; 2.8 m). The 
reaction mixture was stirred at this temperature for 80 min (TLC monitoring), diluted 
with Et2O (30 mL), washed with saturated aq KF (15 mL) and extracted with Et2O (3 x 
30 mL). The organic layer was washed with saturated aq NaHCO3 (10 mL), dried 
(Na2SO4) and concentrated. The resulting residue was purified by column 
chromatography (1:2 EtOAc-petroleum ether) to afford 10 (300 mg, 60% yield). 
Unreacted 9 (150 mg, 27%) was also recovered also recovered. Compound 10 had Rf 
0.77 (2:1 EtOAc-petroleum ether). [α]D +21.6 (c 0.9 in CHCl3). 1H NMR (500 MHz, 
CDCl3) δ 6.17 (dd, 1 H, J5,F = 52.5 Hz, J5,6 = 3.5 Hz, H-5), 5.60 (t, 1 H, J6,7 = J7,8 = 10.0 
Hz, H-7), 5.00 (ddd, 1 H, J6,F = 14.0 Hz, H-6), 4.99 (t, 1 H, J8,8a = 10.0 Hz, H-8), 4.51 
(dd, 1 H, J1a,1b = 9.0 Hz, J1a,8a = 8.0 Hz, H-1a), 4.32 (t, 1 H, J1b,8a = 9.0 Hz, H-1b), 4.17-
4.09 (m, 1 H, H-8a), 2.15-2.09 (3 s, 9 H, MeCO). 13C NMR (125.7 MHz, CDCl3) δ 
170.0-169.5 (MeCO), 154.2 (CO), 87.5 (C-5, d, JC5,F = 211.6 Hz), 72.0 (C-8), 69.8 (C-6, 
d, JC6,F = 24.8 Hz), 68.6 (C-7), 67.2 (C-1), 52.0 (C-8a), 20.4 (MeCO). ESIMS: m/z 
356.1 [M + Na]+. Anal. Calcd for C13H16NO8F: C 46.85, H 4.84, N 4.20. Found: C 
46.77, H 4.71, N 4.02. 
Preparation of (5R and 5S,6R,7S,8R,8aR)-5-Octylthio-6,7,8-trihydroxy-2-
oxa-3-oxoindolizidine (9): To a stirred solution of 9 (59 mg, 0.16 mmol) in anhydrous 
CH2Cl2 (3 mL) at 0 ºC, BF3.Et2O (70 μL, 0.57 mmol and 1-octanethiol (58 μL, 0.33 
mmol) were dropwise added under N2 atmosphere. The mixture was stirred for 15 min 
(TLC monitoring), diluted with CH2Cl2 (25 mL) and washed with water (5 mL), aq 
NaHCO3 (5 mL) and water (5 mL), dried (Na2SO4) and concentrated to afford the 
corresponding octyl thioglycoside 9 (α:β ratio 20:1; H-5 integration). The pure anomers 
9α and 9β were obtained in pure form after subsequent column chromatography (2:3 
EtOAc-petroleum ether). 
(5R,6R,7S,8R,8aR)-5-Octylthio-6,7,8-tri-O-acetyl-2-oxa-3-oxoindolizidine 
(9α):. Yield: 24 mg (73%). Rf 0.75 (1:1 EtOAc-petroleum ether). [α]D +70.8 (c 0.7 in 
CHCl3). 1H NMR (500 MHz, CDCl3) δ 5.69 (d, 1 H, J5,6 = 6.0 Hz, H-5), 5.44 (t, 1 H, 
J6,7 = J7,8 = 10.0 Hz, H-7), 4.97 (dd, 1 H, H-6), 4.94 (t, 1 H, J8a,8 = 9.5 Hz, H-8), 4.47 
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(dd, 1 H, J1a,1b = 9.5 Hz, J1a,8a = 8.5 Hz, H-1a), 4.30 (dd, 1 H, J1b,8a = 6.5 Hz, H-1b), 
4.18 (ddd, 1 H, H-8a), 2.63 (ddd, 1 H, 2JH,H = 12.5 Hz, 3JH,H = 8.5 Hz, 3JH,H = 7.0 Hz, 
SCH2), 2.49 (ddd, 1 H, SCH2), 2.11-2.05 (3 s, 9 H, MeCO), 1.68-1.50 (m, 2 H, 
SCH2CH2), 1.42-1.24 (m, 10 H, CH2), 0.89 (t, 3 H, 3JH,H = 7.0 Hz, CH3). 13C NMR 
(125.7 MHz, CDCl3) δ 170.0-169.5 (MeCO), 155.3 (CO), 72.6 (C-8), 70.2 (C-6), 69.9 
(C-7), 66.2 (C-1), 57.7 (C-5), 51.2 (C-8a), 31.8-22.6 (CH2), 20.6-20.5 (MeCO), 14.1 
(CH3). ESIMS: m/z 481.8 [M + Na]+. Anal. Calcd for C21H33NO8S: C 54.88, H 7.24, N 
3.05, S 6.98. Found: C 54.75, H 7.12, N 2.89, S 6.67. 
(5S,6R,7S,8R,8aR)-5-Octylthio-6,7,8-tri-O-acetyl-2-oxa-3-oxoindolizidine 
(9β): Yield: 4 mg (12%). Rf 0.53 (1:1 EtOAc-petroleum ether). [α]D -9.0 (c 0.3 in 
CHCl3). 1H NMR (500 MHz, CDCl3) δ 5.29 (dd, 1 H, J8a,8 = 10.5 Hz, J7,8 = 7.0 Hz, H-
8), 5.23 (t, 1 H, J5,6 = J6,7 = 4.0 Hz, H-6), 5.12 (dd, 1 H, H-7),4.72 (d, 1 H, H-5), 4.42 (t, 
1 H, J1a,1b = J1a,8a = 8.0 Hz, H-1a), 4.17 (t, 1 H, J1b,8a = 9.0 Hz, H-1b), 4.00 (ddd, 1 H, H-
8a), 2.96-2.84 (m, 2 H, SCH2), 2.15-2.10 (3 s, 9 H, MeCO), 1.70-1.20 (m, 12 H, CH2), 
0.90 (t, 3 H, 3JH,H = 7.0 Hz, CH3). 13C NMR (125.7 MHz, CDCl3) δ 169.9-168.7 
(MeCO), 156.1 (CO), 73.6 (C-7), 73.3 (C-6), 72.7 (C-8), 67.2 (C-1), 59.1 (C-5), 53.9 
(C-8a), 34.3-22.6 (CH2), 20.9-20.6 (MeCO), 14.1 (CH3). ESIMS: m/z 482.2 [M + Na]+. 
HRFABMS Calcd for C21H33NO8SNa [M + Na]+ 482.1825, found 482.1830. 
(5R,6R,7S,8R,8aR)-5-Octylthio-6,7,8-trihydroxy-2-oxa-3-oxoindolizidine 
(7α): Compound 7α was obtained by conventional de-O-acetylation of 10α (54 mg, 
0.12 mmol) with NaOMe in MeOH and purified by olumn chromatography (EtOAc). 
Yield: 36 mg (92%). Rf 0.33 (EtOAc). [α]D +104.2 (c 0.8 in MeOH). 1H NMR (500 
MHz, MeOD) δ 5.28 (d, 1 H, J5,6 = 5.5 Hz, H-5), 4.58 (t, 1 H, J1a,8a = J1a,1b = 8.5 Hz, H-
1a), 4.30 (dd, 1 H, J1b,8a = 5.5 Hz, H-1b), 3.95 (td, 1 H, J8a,8 = 8.5 Hz, H-8a), 3.68 (dd, 1 
H, J6,7 = 9.5 Hz, H-6), 3.55 (t, 1 H, J7,8 = 9.5 Hz, H-7), 3.37-3.31 (m, 1 H, H-8), 2.60 
(ddd, 1 H, 2JH,H = 13.0 Hz, 3JH,H = 8.0 Hz, 3JH,H = 6.0 Hz, SCH2), 2.53 (ddd, 1 H, 
SCH2), 1.72-1.56 (m, 2 H, SCH2CH2), 1.48-1.28 (m, 10 H, CH2), 0.92 (t, 3 H, 3JH,H = 
7.0 Hz, CH3). 13C NMR (125.7 MHz, MeOD) δ 157.0 (CO), 74.3 (C-8), 73.8 (C-7), 
71.1 (C-6), 66.9 (C-1), 61.0 (C-5), 53.1 (C-8a), 31.6-22.3 (CH2), 13.0 (CH3). ESIMS: 
m/z 355.8 [M + Na]+. Anal. Calcd for C15H27NO5S: C 54.03, H 8.16, N 4.20, S 9.62. 
Found: C 53.72, H 7.90, N 4.13, S 9.37. 
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Preparation of (5R and 5S,6R,7S,8R,8aR)-5-octyl-6,7,8-trihydroxy-2-oxa-3-
oxoindolizidine (12): A solution of the fluoro derivative (11, 300 mg, 0.90 mmol, 1.0 
equiv.) in dry toluene (10 mL) under nitrogen atmosphere was cooled to 0 ºC. Then, 
trioctylaluminum (3.8 mL, 1.80 mmol, 2.0 equiv.) was added and the reaction mixture 
was stirred for 3 h (TLC monitoring). A saturated solution of NH4Cl (10 mL) was added 
and the mixture was extracted with EtOAc (3 x 30 mL). The organic phase was dried 
(Na2SO4) and concentrated. The resulting residue was purified by column 
chromatography (1:5 → 1:3.5 EtOAc-petroleum ether) to afford 12 (260 mg, 68%) as a 
mixture of the corresponding α and β anomers (α:β ratio 4:1; H-7 integration). 
Compounds 12α and 12β were separated by HPLC (mobile phase EtOAc:hexane, 
33:67).  
(5R,6S,7R,8R,8aR)-5-Octyl-6,7,8-tri-O-acetyl-2-oxa-3-oxoindolizidine (12α): 
Colourless oil. Retention time HPLC: 23.6 min. Rf 0.51 (1:1 EtOAc-petroleum ether). 
[α]D +36.1 (c 1.0 in CHCl3). 1H NMR (500 MHz, CDCl3) δ 5.34 (t, 1 H, J6,7 = J7,8 = 9.5 
Hz, H-7), 5.04 (dd, 1 H, J5,6 = 6.0 Hz, H-6), 4.96 (t, 1 H, J8,8a = 9.5 Hz, H-8), 4.41 (dd, 1 
H, J1a,1b = 9.0 Hz, J1a,8a = 8.0 Hz, H-1a), 4.27 (dd, 1 H, J1b,8a = 4.5 Hz, H-1b), 4.31-4.24 
(m, 1 H, H-5), 3.82 (ddd, 1 H, H-8a), 2.08-2.04 (3 s, 9 H, MeCO), 1.76-1.53 (m, 2 H, 
CH2), 1.43-1.22 (m, 12 H, CH2), 0.90 (t, 3 H, 3JH,H = 7.0 Hz, CH3). 13C NMR (125.7 
MHz, CDCl3) δ 170.0-169.1 (MeCO), 156.3 (CO), 72.5 (C-8), 69.9 (C-7), 69.7 (C-6), 
65.5 (C-1), 52.1 (C-8a), 51.0 (C-5), 31.8-22.6 (CH2), 20.7-20.6 (MeCO), 14.1 (CH3). 
ESIMS: m/z 450.3 [M + Na]+. Anal. Calcd for C21H33NO8: C 59.00, H 7.78, N 3.28. 
Found: C 59.11, H 7.81, N 3.21. 
(5S,6S,7R,8R,8aR)-5-Octyl-6,7,8-tri-O-acetyl-2-oxa-3-oxoindolizidine (12β): 
White foam. Retention time HPLC: 26.2 min. Rf 0.50 (1:1 EtOAc-petroleum ether). 
[α]D -14.7 (c 1.0 in CHCl3). 1H NMR (500 MHz, CDCl3) δ 5.16 (t, 1 H, J6,7 = J7,8 = 9.5 
Hz, H-7), 5.08 (t, 1 H, J8,8a = 9.5 Hz, H-8), 5.04 (t, 1 H, J5,6 = 9.5 Hz, H-6), 4.33 (dd, 1 
H, J1a,1b = 9.0 Hz, J1a,8a = 7.0 Hz, H-1a), 4.12 (dd, 1 H, J1b,8a = 4.0 Hz, H-1b), 3.70 (ddd, 
1 H, H-8a), 3.31 (td, 1 H, 3JH,H = 4.5 Hz, H-5), 2.40-2.30 (m, 1 H, CH2), 2.08-2.04 (3 s, 
9 H, MeCO), 1.80-1.50 (m, 2 H, CH2), 1.40-1.20 (m, 11 H, CH2), 0.90 (t, 3 H, 3JH,H = 
7.0 Hz, CH3). 13C NMR (125.7 MHz, CDCl3) δ 170.0-169.2 (MeCO), 155.0 (CO), 74.1 
(C-7), 71.1-70.9 (C-6, C-8), 69.4 (C-1), 57.7 (C-8a), 57.4 (C-5), 31.8-22.6 (CH2), 20.6 
(MeCO), 14.1 (CH3). ESIMS: m/z 450.2 [M + Na]+. Anal. Calcd for C21H33NO8: C 
59.00, H 7.78, N 3.28. Found: C 59.08, H 7.69, N 3.20. 
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(5R,6S,7R,8R,8aR)-5-Octyl-6,7,8-trihydroxy-2-oxa-3-oxoindolizidine (8α): 
Compound 8α was obtained by conventional de-O-acetylation of 12α (91 mg, 0.21 
mmol) with NaOMe in MeOH. Yield: 61 mg (95%). Rf 0.75 (9:1 EtOAc-MeOH). [α]D 
+42.3 (c 1.0 in MeOH). 1H NMR (500 MHz, MeOD) δ 4.47 (dd, 1 H, J1a,1b = 9.0 Hz, 
J1a,8a = 8.5 Hz, H-1a), 4.31 (dd, 1 H, J1b,8a = 4.0 Hz, H-1b), 3.92 (ddd, 1 H, 3JH,H = 8.5 
Hz, 3JH,H = 3.0 Hz, J5,6 = 5.5 Hz, H-5), 3.64 (ddd, 1 H, J8,8a = 9.5 Hz, H-8a), 3.52-3.44 
(m, 2 H, H-6, H-7), 3.25 (bt, 1 H, J7,8 = 9.5 Hz, H-8), 1.94-1.85 (m, 1 H, CH2), 1.51-
1.24 (m, 13 H, CH2), 0.92 (t, 3 H, 3JH,H = 7.0 Hz, CH3). 13C NMR (125.7 MHz, MeOD) 
δ 158.3 (CO), 74.1 (C-8), 73.3 (C-7), 70.9 (C-6), 66.1 (C-1), 54.2 (C-5), 53.9 (C-8a), 
31.6-22.3 (CH2), 13.1 (CH3). ESIMS: m/z 324.2 [M + Na]+. Anal. Calcd for C15H27NO5: 
C 59.78, H 9.03, N 4.65. Found: C 59.70, H 8.95, N 4.49. 
 
 S8
 
 
CH NH2
CH NH2
CO
N
O O
HN
HO
HO
HO
H-5 H-1a
H-1b
H-8a
H-7
H-6
H-8
3.43.63.84.04.24.44.6 ppm
C-8
C-7 C-6
C-5
C-1
C-8a
565860626466687072747678 ppm
 
 
1H and 13C NMR spectra (500 MHz, 125.7 MHz, MeOD) of 6α 
 
 
 
 
 
 S9
 
 
 
4.24.44.64.85.05.25.45.65.86.06.26.4 ppm
H-5
H-7
H-6
H-8
H-1a
H-1b
H-8a
CO
MeCO
MeCO505560657075808590 ppm
C-5
C-8
C-7
C-1
C-8a
C-6
N
AcO
AcO
AcO
O O
F
 
 
1H and 13C NMR spectra (500 MHz and 125.7 MHz, CDCl3) of 11 
 
 S10
 
 
50525456586062646668707274 ppm
C-8
C-6 C-7
C-1 C-5 C-8a
COMeCO
H-5
SCH
2
H-7
H-6
H-8 H-8a
4.24.44.64.85.05.25.45.65.8 ppm
H-1a
H-1b
N
AcO
AcO
AcO
O O
S
 
 
1H and 13C NMR spectra (500 MHz and 125.7 MHz, CDCl3) of 10α 
 
 
 
 
 
 
 
 
 
 
 S11
 
 
 
4.04.24.44.64.85.05.25.4
H-8
H-6
H-7
H-5
H-1a
H-1b
H-8a
MeCO
CO
SCH
2
C-7
C-6
C-8
C-1 C-5 C-8a
5456586062646668707274 ppm
AcO
N
S
OAc
AcO
O O
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1H and 13C NMR spectra (500 MHz and 125.7 MHz, CDCl3) of 12α 
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1H and 13C NMR spectra (500 MHz and 125.7 MHz, CDCl3) of 12β 
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1H and 13C NMR spectra (500 MHz and 125.7 MHz, MeOD) of 8α 
 
 
 
 
